A Phase I/II Trial of Combination Bortezomib (VELCADE) and Gemcitabine Therapy for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma.
Phase of Trial: Phase I/II
Latest Information Update: 17 Aug 2016
At a glance
- Drugs Bortezomib (Primary) ; Gemcitabine (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 11 Aug 2016 Planned End Date changed from 1 Mar 2017 to 1 Mar 2019.
- 11 Aug 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2018.
- 09 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Mar 2017, as reported by ClinicalTrials.gov.